|Bid||22,040.00 x 7100|
|Ask||22,070.00 x 29700|
|Day's Range||21,970.00 - 22,220.00|
|52 Week Range||21,750.00 - 32,500.00|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||25,034.01|
|Forward Dividend & Yield||2.82 (1.26%)|
|1y Target Est||86.00|
TASE: PRGO) today announced the launch of an AB-rated generic version of Topicort® (desoximetasone)Topical Spray 0.25%. Topicort® Topical Spray is indicated for the treatment of plaque psoriasis in patients 18 years of age or older. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This launch exemplifies Perrigo's ongoing commitment to developing quality, high value alternatives in important treatment categories.
Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration (“FDA”) for this generic product candidate. If approved by the FDA, Perrigo has agreed to commercialize the generic product candidate in the United States.
TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate, 0.05%) Spray brought by Promius Pharma LLC. Terms of the settlement are confidential. Sernivo® (betamethasone dipropionate, 0.05%) Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older. Annual market sales for the 12 months ending September 2018 were approximately $13 million as measured by IQVIA™. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy.
TASE: PRGO) today announced it has launched its AB rated abbreviated new drug application referencing Solaraze® Gel, 3% (diclofenac sodium gel, 3%). Diclofenac sodium gel, 3% was developed through a pharmaceutical development partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. The product is manufactured by Perrigo and shipping to customers has commenced.
Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "Our R&D team continues its efforts to secure regulatory approvals for important new products. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network.
NESS ZIONA, Israel, Nov. 13, 2018 -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying,.
General Electric Co., Vodafone Group PLC, Ctrip.com International Ltd. and Perrigo Co. PLC have declined to their respective 3-year lows
CEO of Perrigo Co Plc (NYSE:PRGO) Murray S Kessler bought 15,683 shares of PRGO on 11/09/2018 at an average price of $63.79 a share.
Perrigo lost $12.26, or 16.3%, to $62.88. Perrigo lowered its full-year guidance, as it now sees EPS between $4.45 and $4.65, down from $4.75 to $4.95, on revenue of $4.72 billion, down from $4.8 billion to $4.9 billion. Leerink’s Ami Fada reiterated a Market Perform rating on the stock, writing that “once again the top line continues to be weak and 2018 guidance was lowered primarily due to the prescription segment.” While this “shouldn’t be a complete surprise given prescription trends,” she expected the stock to be weak on the news.
The S&P 500 inched lower on Thursday, as disappointing results from a slew of companies, including Qualcomm Inc, countered gains in bank stocks ahead of the Federal Reserve's interest rate decision. Among the biggest decliners on the benchmark index were Perrigo Co, Wynn Resorts Ltd and D.R. Horton Inc, all falling on disappointing quarterly results.
STOCKSTOWATCHTODAY BLOG One day after the Dow Jones Industrial Average rose more than 500 points, the Dow has advanced 55.40 points, or 0.2%, to 26,235.70, while the S&P 500 has dipped 0.1%, to 55.40, and the Nasdaq Composite has declined 0.
The S&P 500 and the Nasdaq edged lower on Thursday, as weak earnings reports and caution ahead of the Federal Reserve's interest rate decision stalled a rally from the previous session, which was spurred by the outcome for midterm elections. Among the biggest deliners on the S&P 500 were Perrigo Co , Wynn Resorts Ltd and D.R. Horton Inc, all falling on disappointing quarterly results.
Perrigo shares fell sharply after the report and are down nearly 30% so far this year. Perrigo said on the call that problems included an “absence of new products, price erosion in authorized generic products and customer-service challenges resulting in lower sales volumes.” Perrigo plans to sell or spin off the generics business, but it is hard to imagine a buyer will pay a good price to own what is clearly a troubled operation. Perrigo won’t provide financial guidance for 2019 until February, but another decline would mark three consecutive years of falling profits.
Perrigo (PRGO) reports mixed third-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018 for the second straight quarter.
U.S. stocks edged lower on Thursday, as a clutch of weak earnings reports punctured a rally from the previous session, which was spurred by the outcome for midterm elections. Wynn Resorts Ltd, Perrigo Co and D.R. Horton Inc were the biggest losers on the S&P 500, all falling after reporting disappointing quarterly results. Qualcomm Inc dropped 7.1 percent after the chipmaker forecast sales revenue for the holiday shopping quarter below analysts' estimates, as it took a hit from the loss of chip sales to Apple Inc.
Perrigo (PRGO) delivered earnings and revenue surprises of 3.81% and -3.23%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Dublin-based company said it had a loss of 49 cents. Earnings, adjusted for one-time gains and costs, came to $1.09 per share. The results beat Wall Street expectations. The average ...
DUBLIN , Nov. 8, 2018 /PRNewswire/ -- Realized third quarter 2018 GAAP ("reported") net sales of $1.1 billion , reported net loss of $68 million compared to a net income of $45 million last year ...
Perrigo (NYSE: PRGO ) announces its next round of earnings this Thursday, Nov. 8. Here's Benzinga's advanced look at Perrigo's Q3 earnings report. Earnings and Revenue Wall Street analysts see Perrigo ...
Perrigo (PRGO) focuses on growth strategy for Consumer Healthcare Americas segment. The company plans to divest its loss-making Rx segment.